TraceLink Propels Organizations Toward DSCSA Compliance Ahead of the November 2024 Deadline

September 28, 2024 12:00 AM AEST | By Cision
 TraceLink Propels Organizations Toward DSCSA Compliance Ahead of the November 2024 Deadline
Image source: Kalkine Media

BOSTON, Sept. 27, 2024 /PRNewswire/ -- With the Drug Supply Chain Security Act (DSCSA) stabilization period ending on November 27, 2024, the TraceLink customer and trading partner community of healthcare and life sciences companies continues to demonstrate market leadership in demonstrating compliance readiness. TraceLink's 290,000-strong B2N Integrate-Once™network has been instrumental in supporting customers to rapidly integrate with key supply chain partners, exchange required compliance information, automate compliance processes, and mitigate operational risks.

In the past 90 days, TraceLink customers have exchanged over 6 million DSCSA Electronic Product Code Information Services (EPCIS) transactions, reflecting a significant surge in compliance activities. Impressively, 43% of all EPCIS transactions over the past 12 months occurred during this period, underscoring the momentum of compliance initiatives as companies race to meet the deadline. Additionally, 2,590 new links with supply chain partners were established, enabling over 2,010 companies and 540 customers to seamlessly exchange critical EPCIS data.

TraceLink's customer base has exchanged more than 15 million DSCSA transactions to date, and has grown to more than 850 companies, ranging across pharmaceutical manufacturers, contract manufacturers, wholesale distributors, and dispensers. This significant increase highlights the urgency and trust that companies place in TraceLink's ability to deliver compliance solutions swiftly and efficiently.

"Partnering with TraceLink has been transformative for Techdow in achieving DSCSA compliance at record speed," said Bilal Khan, CEO of Techdow USA. "The TraceLink team's expertise and commitment to customer success facilitated a seamless and rapid deployment, enabling us to meet regulatory requirements swiftly. Their responsiveness and dedication have been instrumental in enhancing the security and transparency of our supply chain, allowing us to continue delivering safe, high-quality medications to patients with full confidence."

For organizations still concerned about their DSCSA readiness or those who have not yet started the process, there is still time to act. TraceLink's B2N Integrate-Once™ network enables rapid compliance through a network of pre-verified trading partners, providing a streamlined path to meeting regulatory standards without operational disruption.

TraceLink has established itself as a leader in DSCSA compliance by not only enabling predictable, cost-effective integration capability but also by providing customers with a suite of resources designed to support their compliance and digital network journey through value expansion. These include:

  • Network Success Management: A dedicated team that provides expert guidance and support to onboard partners quickly and efficiently, ensuring they can link to TraceLink's network and start exchanging EPCIS transactions without delays.
  • Comprehensive Training & Education: Through TraceLink University, customers have access to a full catalog of online courses, workshops, monthly newsletters, and certification classes tailored to all stages of the DSCSA compliance process.
  • Monthly Community Forums: TraceLink hosts multiple monthly meetings offering manufacturers, wholesale distributors, and dispensers an opportunity to discuss DSCSA tracing and verification compliance, FDA actions, and industry initiatives, fostering collaboration and knowledge sharing.
  • Companion Compliance Capabilities for Operational Excellence: TraceLink offers solutions to operationalize DSCSA compliance, including serialized receiving and shipping, drop shipment support, GTIN and pack level master data sharing, suspect product verification, compliance exception management, and automated validation.

"TraceLink is committed to helping our customers seamlessly achieve DSCSA compliance as we near the end of the stabilization period," said Shabbir Dahod, President and CEO of TraceLink. "As companies continue to focus on meeting the DSCSA's requirements, our suite of comprehensive solutions and support resources ensure that businesses, regardless of where they are on their compliance journey, can effectively link with supply chain partners and avoid disruptions to their operations."

TraceLink is helping companies leverage their DSCSA investment to improve compliance exception management, digitalize their recall processes, and orchestrate other supply chain transactions. By expanding the use of their DSCSA data and network connections, companies can enhance operational efficiency and streamline critical business processes beyond compliance. For more information on how TraceLink can support your organization in meeting DSCSA requirements, visit TraceLink.com.

About TraceLink

TraceLink is the leading digital network platform company that enables end-to-end supply chain visibility and intelligence. With the largest integrated digital supply network in the life sciences and healthcare industry, TraceLink links the global life sciences supply chain and delivers complete digital transformation solutions for companies seeking to comply with complex global track and trace regulations. For more information, visit www.tracelink.com.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.